Nuformix plc (NFX) Ordinary 0.1p Shares
Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002. Its pre-clinical pipeline includes NXP003. It is developing NXP001 for oncology supportive care. It is developing NXP002 for the treatment of multiple fibrotic diseases. NXP003 targets a mechanism understood to confer resistance to immuno-oncology, chemotherapy and radiotherapy cancer treatments.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.